AstraZeneca · 1 day ago
Clinical Demand/Supply Planning Intern (Graduate)
AstraZeneca is seeking Master's students for a Clinical Demand/Supply Planning Intern role at their Alexion: AstraZeneca Rare Disease site in Boston, MA. The internship focuses on optimizing outputs, improving data management, and enhancing collaboration between planning teams and stakeholders.
BiopharmaBiotechnologyHealth CareMedicalPharmaceuticalPrecision Medicine
Responsibilities
Optimize routine C&OP outputs to provide current state updates to leadership
Improve team data management and dashboarding to standardize practices and align outcomes. (Waste/Obsolescence)
Improve ways or working between Demand/Supply planning teams and external stakeholders
Qualification
Required
Master's students majoring in Business, Finance, Pharmacy, Biology, Chemical Engineering, Biotechnology, or a related field
Candidates must have an expected graduation date after August 2026
US Work Authorization is required at time of application
Ability to report onsite to the Seaport neighborhood in Boston, MA site 4 days per week
Preferred
Data analysis experience with Excel
Visualization tools experience such as PowerBI
Experience with Smartsheets
Prior experience leading complex projects and presenting to key stakeholders
Enthusiasm for collaboration, cross-functional projects, public speaking, and presentation design
Benefits
Short-term incentive bonus opportunity
Equity-based long-term incentive program (salaried roles)
Retirement contribution (hourly roles)
Commission payment eligibility (sales roles)
Qualified retirement program [401(k) plan]
Paid vacation and holidays
Paid leaves
Health benefits including medical, prescription drug, dental, and vision coverage
Company
AstraZeneca
AstraZeneca is a pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines. It is a sub-organization of Investor.
Funding
Current Stage
Public CompanyTotal Funding
$5.26B2024-07-30Post Ipo Debt· $1.51B
2023-02-28Post Ipo Debt· $2.25B
2023-02-24Post Ipo Debt· $1.5B
Leadership Team
Recent News
2026-01-09
2026-01-09
News Powered by Cision
2026-01-08
Company data provided by crunchbase